Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results
- Positive Phase 3 results for fasedienol in the treatment of social anxiety disorder (SAD)
- Secured $137.7 million in gross proceeds, including $100 million from an underwritten public offering of equity securities
- Preparations underway for potential NDA-enabling Phase 3 studies in 2024
- None.
- Fasedienol (PH94B) PALISADE Phase 3 Program for acute treatment of social anxiety disorder (SAD) advancing to build on recent positive PALISADE-2 Phase 3 results
- Preparations to initiate potential fasedienol NDA-enabling Phase 3 studies in 2024 underway
- Itruvone (PH10) staged for potential Phase 2B clinical development 2H 2024
- PH80 positive exploratory Phase 2A trial data reported in two separate women’s health indications – vasomotor symptoms (hot flashes) due to menopause and premenstrual dysphoric disorder (PMDD)
-
$137.7 million $100 million
-
Strong financial position provides adequate cash runway to a potential fasedienol
U.S. New Drug Application for acute treatment of SAD
“Vistagen achieved multiple important milestones in recent months, significantly advancing our innovative pipeline, including positive Phase 3 results for fasedienol, our lead pherine nasal spray drug candidate,” said Shawn Singh, Chief Executive Officer. “With a fortified balance sheet, a robust pipeline of drug candidates differentiated from the current standards of care, and a clear path forward in our potential
Corporate Update and Pipeline Highlights
Fasedienol Nasal Spray – PALISADE Phase 3 Program
Positive results in August 2023 from PALISADE-2 Phase 3 study of fasedienol for the acute treatment of anxiety in adults with SAD advances the PALISADE Phase 3 development program and paves the way to initiate potential
- Primary endpoint met, with fasedienol demonstrating a statistically significant difference in average patient-reported Subjective Units of Distress Scale (SUDS) score during a public speaking challenge compared to placebo (p=0.015).
- Secondary endpoint met, demonstrating a statistically significant difference in the proportion of clinician-assessed responders between fasedienol and placebo as measured by the Clinical Global Impressions - Improvement (CGI-I) scale (p=0.033).
- Exploratory endpoint met, demonstrating a statistically significant difference in the proportion of patient-assessed responders between fasedienol and placebo as measured by the Patient Global Impression of Change (PGI-C) scale (p=0.003).
- Fasedienol was observed to be well-tolerated and demonstrated a favorable safety profile consistent with all prior trials.
-
PALISADE Phase 3 Program studies to be initiated in 2024 are designed to build on the positive results observed from PALISADE-2 and enable a potential submission of a fasedienol
U.S. NDA in SAD.
Preparing to initiate PALISADE-3 and PALISADE-4 Phase 3 studies.
To complement the positive top-line results from PALISADE-2, the Company is preparing to launch two similar Phase 3 clinical trials in 2024, PALISADE-3 in the first half of 2024 and PALISADE-4 in the second half of 2024. Like PALISADE-2, each study will be a randomized, double-blind, placebo-controlled, Phase 3 clinical trial designed to evaluate the efficacy, safety, and tolerability of the acute administration of fasedienol to relieve anxiety symptoms in adult patients with SAD after a single dose of fasedienol during a simulated, anxiety-provoking public speaking challenge in a clinical setting, as measured using the patient-reported SUDS as the primary efficacy endpoint.
Should it be successful, the Company believes its PALISADE Phase 3 Program may establish substantial evidence of fasedienol’s effectiveness, supporting a potential fasedienol NDA submission to the
The Company also plans to initiate a small (n= ca. 60) three-arm randomized, double-blind, placebo-controlled Phase 2B clinical trial designed to evaluate the efficacy, safety, and tolerability of a repeat dose of fasedienol (administered 10 minutes after an initial dose) to further relieve symptoms of acute anxiety in adult patients with SAD during a single simulated, anxiety-provoking public speaking challenge in a clinical setting.
The Company is preparing for the following milestones for fasedienol in SAD:
- Initiate PALISADE-3 Phase 3 study in the first half of 2024;
- Initiate PALISADE-4 Phase 3 study in the second half of 2024; and
- Initiate fasedienol Phase 2B repeat dose study in the second half of 2024.
Itruvone Nasal Spray
Itruvone staged for Phase 2B development as a monotherapy for major depressive disorder (MDD), by the Company or potentially with a strategic partner.
In June 2023, the Company completed a successful randomized, double-blind, placebo-controlled Phase 1 clinical trial to investigate the safety and tolerability of itruvone in healthy adult subjects. The trial was designed to confirm the favorable safety profile of itruvone established in three previous clinical trials conducted in
The Company is preparing for the following milestone for itruvone in MDD:
- Initiate Phase 2B study in the second half of 2024.
PH80 Nasal Spray
Second positive exploratory Phase 2A trial of hormone-free PH80 nasal spray provides new optimism for the acute management of multiple indications in women’s healthcare with high unmet medical need.
In September 2023, the Company announced previously unreported data of a randomized, double-blind, placebo-controlled exploratory Phase 2A clinical study designed to explore the efficacy, safety, and tolerability of intranasal administration of PH80 for the acute management of premenstrual dysphoric disorder (PMDD) in subjects with a regular menstrual cycle and at least a one-year history of PMDD.
- PH80 demonstrated statistically and clinically significant improvement versus placebo in symptoms of PMDD using the subject-rated Penn Daily Symptom Report (DSR) as early as Day 4 and continuing to Day 6 (p=0.008).
- PH80 demonstrated statistically and clinically significant improvement versus placebo at Day 6 on the clinician-rated Premenstrual Tension Scale (PMTS) (p=0.006).
- PH80 was well-tolerated with no serious adverse events.
- Along with the positive results reported during the Company’s fiscal 2024 first quarter from a randomized, double-blind, placebo-controlled exploratory Phase 2A clinical study designed to explore the efficacy, safety, and tolerability of PH80 for the acute management of vasomotor symptoms (hot flashes) due to menopause, these PMDD data further support PH80’s potential as a differentiated, non-systemic, hormone-free treatment option for multiple indications in women’s healthcare with high unmet medical need.
The Company expects the following milestone for PH80:
-
Finalize
U.S. IND-enabling studies in the second half of 2024 to facilitate potential Phase 2B development in theU.S. for the acute treatment of vasomotor symptoms (hot flashes) due to menopause in the first half of 2025, potentially with a development and commercialization partner.
Corporate Update
In September 2023, Vistagen and Fuji Pharma entered into a time-limited (up to approximately eighteen months) agreement to negotiate exclusively with each other regarding a potential license to develop and commercialize PH80 in
Cindy Anderson appointed as Chief Financial Officer, succeeding Jerrold Dotson who retired after a distinguished decade-long career with the Company.
In August 2023, the Company announced the appointment of Cindy Anderson as Chief Financial Officer. Ms. Anderson brings almost two decades of financial and operating strength from her experiences in the biotechnology sector. She joins Vistagen from Alnylam Pharmaceuticals where she served as the Chief Accounting Officer, focused on strategic and financial operations. Vistagen would like to extend its gratitude to Mr. Dotson for his substantial contributions during his tenure with the Company.
Fiscal Year 2024 Second Quarter Financial Results
Research and development (R&D) expense: Research and development expense decreased by approximately
General and administrative (G&A) expense: General and administrative expense decreased by approximately
Net loss: Net loss attributable to common stockholders for the second quarter ended September 30, 2023 was approximately
Cash position: At September 30, 2023, the Company had cash and cash equivalents of approximately
Should its PALISADE Phase 3 Program be successful, the Company believes that the current cash position will be sufficient to fund its operations through its potential submission of a
As of November 9, 2023, the Company had 27,023,038 shares of common stock outstanding.
Conference Call
Vistagen will host a conference call and live audio webcast this afternoon at 5:00 p.m. Eastern Time to provide a corporate update.
International Dial-in Number (Toll): 1-203-518-9765
Conference ID: VISTAGEN
Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1641124&tp_key=2213157260
A live audio conference call webcast will also be available via the above link. Participants should access this webcast site 10 minutes before the start of the call. In addition, a telephone playback of the call will be available after approximately 8:00 p.m. Eastern Time on Thursday, November 9, 2023. To listen to the replay, call toll-free 1-844-512-2921 within
About Vistagen
Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders. Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently available for the treatment of anxiety, depression, and multiple CNS disorders. Vistagen's pipeline contains six clinical-stage product candidates, including fasedienol (PH94B), itruvone (PH10), PH15, PH80, and PH284, each an investigational agent belonging to a new class of drugs known as pherines, as well as AV-101, which is an oral prodrug antagonist of the N-methyl-D-aspartate receptor (NMDAR). Pherines are neuroactive nasal sprays designed with an innovative and differentiated proposed mechanism of action (MOA) that activates chemosensory neurons in the nasal cavity and can beneficially impact key neural circuits in the brain without systemic absorption or direct activity on neurons in the brain. Vistagen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety, depression, and several other CNS disorders. Connect at www.Vistagen.com.
Forward-looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. These forward-looking statements involve known and unknown risks that are difficult to predict and include all matters that are not historical facts. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," “expect,” “project,” “outlook,” “strategy,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “strive,” “goal,” “continue,” “likely,” “will,” “would” and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by Vistagen and its management, are inherently uncertain. As with all pharmaceutical products, there are substantial risks and uncertainties in the process of development and commercialization and actual results or developments may differ materially from those projected or implied in these forward-looking statements. Among other things, there can be no guarantee that any of the Company’s drug candidates will successfully complete ongoing or, if initiated, future clinical trials, receive regulatory approval or be commercially successful, or that the Company will be able to successfully replicate the result of past studies of its product candidates, including fasedienol, itruvone, AV-101 and/or PH80. Other factors that may cause such a difference include, without limitation, risks and uncertainties relating to the Company’s submission of an
| VISTAGEN THERAPEUTICS, INC. | |||||||
| CONSOLIDATED BALANCE SHEETS | |||||||
| (Amounts in dollars, except share amounts) | |||||||
September 30, |
|
March 31, |
|||||
2023 |
|
2023 |
|||||
(Unaudited) |
|
|
|||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ |
37,608,400 |
|
$ |
16,637,600 |
|
|
| Prepaid expenses and other current assets |
|
1,393,300 |
|
|
802,700 |
|
|
| Deferred contract acquisition costs - current portion |
|
74,500 |
|
|
67,100 |
|
|
| Total current assets |
|
39,076,200 |
|
|
17,507,400 |
|
|
| Property and equipment, net |
|
444,300 |
|
|
507,300 |
|
|
| Right-of-use asset - operating lease |
|
2,045,000 |
|
|
2,260,300 |
|
|
| Deferred offering costs |
|
362,000 |
|
|
495,700 |
|
|
| Deferred contract acquisition costs - non-current portion |
|
167,400 |
|
|
217,600 |
|
|
| Security deposits |
|
100,900 |
|
|
100,900 |
|
|
| Total assets | $ |
42,195,800 |
|
$ |
21,089,200 |
|
|
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ |
1,305,000 |
|
$ |
2,473,100 |
|
|
| Accrued expenses |
|
292,600 |
|
|
787,400 |
|
|
| Note payable |
|
- |
|
|
105,300 |
|
|
| Deferred revenue - current portion |
|
793,000 |
|
|
714,300 |
|
|
| Operating lease obligation - current portion |
|
517,100 |
|
|
485,600 |
|
|
| Financing lease obligation - current portion |
|
1,800 |
|
|
1,700 |
|
|
| Total current liabilities |
|
2,909,500 |
|
|
4,567,400 |
|
|
| Non-current liabilities: | |||||||
| Deferred revenue - non-current portion |
|
1,780,600 |
|
|
2,314,600 |
|
|
| Operating lease obligation - non-current portion |
|
1,854,000 |
|
|
2,119,800 |
|
|
| Financing lease obligation - non-current portion |
|
6,500 |
|
|
7,400 |
|
|
| Total non-current liabilities |
|
3,641,100 |
|
|
4,441,800 |
|
|
| Total liabilities |
|
6,550,600 |
|
|
9,009,200 |
|
|
| Commitments and contingencies (Note 9) | |||||||
| Stockholders’ equity: | |||||||
| Preferred stock, |
|
- |
|
|
- |
|
|
| Common stock, |
|
12,000 |
|
|
7,300 |
|
|
| Additional paid-in capital |
|
379,943,800 |
|
|
342,892,500 |
|
|
| Treasury stock, at cost, 4,522 shares of common stock held at September 30, 2023 and March 31, 2023 |
|
(3,968,100 |
) |
|
(3,968,100 |
) |
|
| Accumulated deficit |
|
(340,342,500 |
) |
|
(326,851,700 |
) |
|
| Total stockholders’ equity |
|
35,645,200 |
|
|
12,080,000 |
|
|
| Total liabilities and stockholders’ equity | $ |
42,195,800 |
|
$ |
21,089,200 |
|
|
| References to common shares and per share amounts have been retroactively restated to reflect the Company’s 1-for-30 reverse stock split of its common stock effective on June 6, 2023. | |||||||
| VISTAGEN THERAPEUTICS | |||||||||||||||
| CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS | |||||||||||||||
| (Unaudited) | |||||||||||||||
| (Amounts in Dollars, except share amounts) | |||||||||||||||
Three Months Ended |
|
Six Months Ended |
|||||||||||||
September 30, |
|
September 30, |
|||||||||||||
2023 |
|
2022 |
|
2023 |
|
2022 |
|||||||||
| Revenues: | |||||||||||||||
| Sublicense revenue | $ |
277,700 |
|
$ |
(892,500 |
) |
$ |
455,300 |
|
$ |
(582,500 |
) |
|||
| Total revenues |
|
277,700 |
|
|
(892,500 |
) |
|
455,300 |
|
|
(582,500 |
) |
|||
| Operating expenses: | |||||||||||||||
| Research and development |
|
3,850,600 |
|
|
12,894,500 |
|
|
8,047,800 |
|
|
28,185,800 |
|
|||
| General and administrative |
|
3,207,300 |
|
|
3,702,300 |
|
|
6,185,500 |
|
|
8,494,100 |
|
|||
| Total operating expenses |
|
7,057,900 |
|
|
16,596,800 |
|
|
14,233,300 |
|
|
36,679,900 |
|
|||
| Loss from operations |
|
(6,780,200 |
) |
|
(17,489,300 |
) |
|
(13,778,000 |
) |
|
(37,262,400 |
) |
|||
| Other income, net: | |||||||||||||||
| Interest income, net |
|
192,500 |
|
|
6,100 |
|
|
289,700 |
|
|
8,400 |
|
|||
| Loss before income taxes |
|
(6,587,700 |
) |
|
(17,483,200 |
) |
|
(13,488,300 |
) |
|
(37,254,000 |
) |
|||
| Income taxes |
|
- |
|
|
- |
|
|
(2,500 |
) |
|
(5,500 |
) |
|||
| Net loss and comprehensive loss | $ |
(6,587,700 |
) |
$ |
(17,483,200 |
) |
$ |
(13,490,800 |
) |
$ |
(37,259,500 |
) |
|||
| Basic and diluted net loss per common share | $ |
(0.66 |
) |
$ |
(2.54 |
) |
$ |
(1.55 |
) |
$ |
(5.41 |
) |
|||
| Weighted average common share - basic and diluted |
|
10,042,530 |
|
|
6,893,708 |
|
|
8,717,050 |
|
|
6,890,152 |
||||
| References to common shares and per share amounts have been retroactively restated to reflect the Company’s 1-for-30 reverse stock split of its common stock effective on June 6, 2023. | |||||||||||||||
View source version on businesswire.com: https://www.businesswire.com/news/home/20231109410625/en/
Investors:
Mark McPartland
Senior Vice President, Investor Relations
(650) 577-3606
markmcp@vistagen.com
Media:
Nate Hitchings
SKDK
nhitchings@skdknick.com
Source: Vistagen
FAQ
What are the recent milestones achieved by Vistagen (Nasdaq: VTGN)?
What is the financial position of Vistagen (Nasdaq: VTGN)?
What is the potential impact of the positive Phase 3 results on Vistagen's stock performance?
What are the future milestones for Vistagen (Nasdaq: VTGN)?
Who was appointed as the Chief Financial Officer of Vistagen (Nasdaq: VTGN)?
